毕得医药: 股东减持股份计划公告

Core Viewpoint - The major shareholders of Shanghai Bid Pharmaceutical Technology Co., Ltd. plan to reduce their holdings due to liquidity needs, with specific details on the number of shares and methods of reduction outlined in the announcement [1][2][4]. Shareholder Information - The major shareholder, Zhoushan Xinxie Enterprise Management Partnership (Limited Partnership), holds 5,019,806 shares, accounting for 5.52% of the total shares [1][2]. - Another shareholder, Ningbo Landan Enterprise Management Partnership (Limited Partnership), holds 4,305,076 shares, representing 4.74% of the total shares [3][4]. - The total shares held by Zhoushan Xinxie, Ningbo Landan, and their associated party, Wu Bo, amount to 11.12% of the company [1][4]. Reduction Plan Details - Zhoushan Xinxie plans to reduce up to 908,829 shares, not exceeding 1.00% of the total share capital, through block trading [2][5]. - Ningbo Landan also intends to reduce up to 908,829 shares, with the same percentage limit and method [2][5]. - Wu Bo plans to reduce up to 785,804 shares through centralized bidding, which is 0.86% of the total shares [2][5]. Reduction Timeline - The reduction period is set from September 29, 2025, to December 28, 2025 [5][6]. Shareholding Source - The shares held by Zhoushan Xinxie and Ningbo Landan were acquired before the company's initial public offering (IPO) and through capital reserve conversion [2][4]. - Wu Bo's shares were obtained through a non-trading transfer after the dissolution of the original shareholder, Dinghua Yongchuan Venture Capital Partnership (Limited Partnership) [4][5]. Compliance and Commitments - The major shareholders have made commitments regarding their shareholding, including a lock-up period for shares acquired before the IPO [6][7]. - The shareholders will comply with relevant laws and regulations during the reduction process, ensuring that the actions do not affect the company's governance structure or control [10][11].